Irreversible electroporation therapy in the liver: longitudinal efficacy studies in a rat model of hepatocellular carcinoma.
Irreversible electroporation (IRE) is an innovative local-regional therapy that involves delivery of intense electrical pulses to tissue to induce nanoscale cell membrane defects for tissue ablation. The purpose of this study was to investigate the feasibility of using IRE as a liver-directed ablation technique for the treatment of hepatocellular carcinoma (HCC). In the N1-S1 rodent model, hepatomas were grown in 30 Sprague-Dawley rats that were divided into treatment and control groups. For treatment groups, IRE electrodes were inserted and eight 100-mus 2,500-V pulses were applied to ablate the targeted tumor tissues. For both groups, magnetic resonance imaging scans were performed at baseline and 15-day follow-up intervals to determine tumor sizes (one-dimensional maximum diameter, D(max); estimated two-dimensional cross-sectional area, C(max)) as a tactic to assess longitudinal outcomes. Additional groups of treated animals were sacrificed at 1-, 3-, and 7-day intervals posttherapy for pathology assessment of treatment response. Magnetic resonance images showed significant tumor size reductions within 15 days posttherapy (32 +/- 31% D(max) and 52 +/- 39% C(max) decreases compared with 110 +/- 35% D(max) and 286 +/- 125% C(max) increases for untreated tumors). Pathology correlation studies documented progression from poorly differentiated viable HCC tissues before treatment to extensive tumor necrosis and full regression in 9 of 10 treated rats 7 to 15 days after treatment. Our findings suggest that IRE can be an effective strategy for targeted ablation of liver tumors, prompting its further evaluation for HCC therapy.
Guo
Yang
Y
Department of Radiology, Northwestern University, Chicago, Illinois 60611, USA.
Zhang
Yue
Y
Klein
Rachel
R
Nijm
Grace M
GM
Sahakian
Alan V
AV
Omary
Reed A
RA
Yang
Guang-Yu
GY
Larson
Andrew C
AC
D055011:Ablation Techniques / Q000379:methods; D000818:Animals; D018952:Antigens, CD34 / Q000378:metabolism; D006528:Carcinoma, Hepatocellular / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D053672:Electrochemotherapy / Q000379:methods*; D007150:Immunohistochemistry; D008099:Liver / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D008114:Liver Neoplasms, Experimental / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D008137:Longitudinal Studies; D008279:Magnetic Resonance Imaging; D008297:Male; D009368:Neoplasm Transplantation; D011859:Radiography; D051381:Rats; D017207:Rats, Sprague-Dawley; D016896:Treatment Outcome; D014407:Tumor Cells, Cultured
D018952:Antigens, CD34